Enanta Pharmaceuticals, Inc.
ENTA · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | 0.13 | -0.22 | -0.17 |
| FCF Yield | -12.60% | -44.12% | -47.91% | -8.13% |
| EV / EBITDA | -5.59 | -3.90 | -3.01 | -8.82 |
| Quality | ||||
| ROIC | -31.44% | -33.76% | -31.87% | -34.89% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.24 | 0.68 | 0.77 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | -6.22% | -7.75% | -6.56% | -11.06% |
| Free Cash Flow Growth | 66.74% | 13.81% | -29.12% | -22.84% |
| Safety | ||||
| Net Debt / EBITDA | -2.22 | -1.81 | -1.11 | 0.15 |
| Interest Coverage | -11.11 | -11.12 | -26.65 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 38.45 | 208.55 | 182.57 | 207.73 |